middle.news
Telix Surpasses FY24 Revenue Targets with US$142M Q4 Surge
5:10pm on Monday 13th of January, 2025 AEDT
•
Biotechnology
Read Story
Telix Surpasses FY24 Revenue Targets with US$142M Q4 Surge
5:10pm on Monday 13th of January, 2025 AEDT
Key Points
Q4 2024 revenue hits US$142 million, up 46% year-on-year
Full-year 2024 revenue reaches US$517 million, surpassing guidance
Progress on multiple therapeutic candidates including TLX591 and TLX250
Acquisition of FAP-targeting assets and antibody platform expands pipeline
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE